- Home
- GTEC vs IGC Comparison
GTEC vs IGC Comparison
Compare GTEC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTEC | IGC |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 31.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTEC | IGC |
|---|---|---|
| Price | $0.99 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 229.3K | ★ 907.7K |
| Earning Date | 11-07-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | $1,106,000.00 |
| Revenue This Year | $5.64 | $3.54 |
| Revenue Next Year | $3.93 | $15.12 |
| P/E Ratio | $1.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $0.25 |
| 52 Week High | $2.92 | $0.50 |
Technical Indicators
Market Signals| Indicator | GTEC | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 37.87 |
| Support Level | $0.95 | $0.32 |
| Resistance Level | $1.15 | $0.36 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 17.04 | 17.35 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.